Marcum Wealth LLC bought a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,325 shares of the company's stock, valued at approximately $295,000.
Several other institutional investors and hedge funds also recently bought and sold shares of SNY. Synergy Asset Management LLC purchased a new position in Sanofi during the fourth quarter valued at $25,000. McClarren Financial Advisors Inc. lifted its position in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi in the fourth quarter valued at about $31,000. Bessemer Group Inc. lifted its position in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new position in shares of Sanofi in the fourth quarter valued at about $44,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently commented on SNY shares. The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Finally, BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $63.33.
View Our Latest Analysis on SNY
Sanofi Price Performance
Shares of SNY stock traded down $2.95 during trading hours on Friday, hitting $49.40. The stock had a trading volume of 4,670,469 shares, compared to its average volume of 2,402,932. Sanofi has a one year low of $45.80 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock's 50-day moving average price is $52.25 and its two-hundred day moving average price is $51.92. The stock has a market capitalization of $121.15 billion, a price-to-earnings ratio of 19.84, a PEG ratio of 1.01 and a beta of 0.55.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. The firm's revenue for the quarter was down 11.0% on a year-over-year basis. Equities analysts forecast that Sanofi will post 4.36 EPS for the current year.
Sanofi Increases Dividend
The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is presently 57.14%.
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
